Bristol Myers Squibb (BMY) Stock Falls Amid Market Uptick: What Investors Need to Know
Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report
Perspective Falls After Data for Radiopharmaceutical in Skin Cancer
Morgan Stanley Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Maintains Target Price $37
Kyverna, Cabaletta Started at Buys by UBS on CAR T Therapy Potential
Correction to Old Drug Repurposed Article on Oct. 7 -- WSJ
BMY Buoyed by Recent Regulatory Updates: How to Play the Stock?
UBS Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $54
TD Cowen Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $59
Barclays Maintains Underweight on Bristol-Myers Squibb, Raises Price Target to $43
Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst
Unveiling 11 Analyst Insights On Bristol-Myers Squibb
Bristol-Myers Squibb Is Maintained at Hold by TD Cowen
Bristol-Myers Squibb Analyst Ratings
10 Health Care Stocks Whale Activity In Today's Session
Top 10 Rated U.S. Value Stocks per SA Quant Metrics
S&P 500 Could Reach 6,300 In 12 Months, Says Goldman Sachs, Driven by 'Strong AI Demand' And 'Margin Expansion'
Pfizer Stock Slump: Will Starboard's Billion-Dollar Bet Spark Rebound?
Express News | Bristol-Myers Squibb Co : TD Cowen Raises Target Price to $59 From $53
Pfizer Gets an Activist. What Starboard's Track Record With Pharma Tells Us. -- Barrons.com